New research may help predict when an individual's HIV infection will progress to clinical AIDS

December 16, 1999

Newly published research led by University of Washington scientists could one day lead to a laboratory test to predict when people infected with human immunodeficiency virus type 1 (HIV-1) are likely to progress to symptomatic AIDS.

Dr. James Mullins, professor and chair of the UW Department of Microbiology, Dr. Raj Shankarappa, UW senior fellow in microbiology, and colleagues at Johns Hopkins University and the University of Pittsburgh report results of their study in the December 1999 issue of the Journal of Virology.

"We have found that there is a previously unrecognized consistency in the evolution of the HIV virus in people who subsequently progress to full-blown AIDS," said Mullins. "This finding allows us to recognize preclinical stages of infection."

The researchers did a retrospective analysis of blood samples provided every six months, beginning in the mid-1980s, by nine HIV-positive gay men enrolled in the Multicenter AIDS Cohort Study.

"Analyzing these sequential blood samples, we found there is predictability in the development of AIDS," said Shankarappa. "It was true of all nine people in this study, and we think it will occur in most cases of AIDS."

As was known previously, immediately after infection with HIV there is an acute stage of a few weeks. Then comes an asymptomatic stage of variable length; finally, the infection progresses to the symptomatic stage of clinical AIDS.

Some people with HIV progress to AIDS within a year of initial infection; the average is about nine years. A few people may never progress to clinical AIDS.

The UW research used a sequential analysis of mutations in the HIV-1 envelope gene to recognize progression within the asymptomatic clinical stage, and thus, the timing of development of full-blown AIDS. The researchers studied the evolution of a region of the HIV-1 envelope gene and of T-cell subsets in the nine men, all of whom had a roughly moderate rate of disease progression. They were monitored for a period of six to 12 years, until development of advanced disease in seven of the men. (None of the participants was prevented from receiving the latest treatment available at the time; in fact, most of the blood samples date from the mid- and late 1980s when therapies such as protease inhibitors were not available.)

The researchers analyzed three factors at sequential time points: how much the virus had mutated from its original form, how diverse the virus population became, and the appearance of X4 viruses, capable of utilizing a T-cell receptor called CXCR4.

Analysis suggested the existence of three distinct phases within the asymptomatic phase of HIV infection: a phase prior to a peak in diversity and the appearance of X4 viruses; a second phase prior to peak representation of X4 viruses and maximal divergence from the original form of virus; and a third phase following those peaks.

"The phases describe a consistent pattern of viral evolution during the course of HIV-1 infection in moderate progressors," report the researchers. "Recognition of this pattern may help explain previous conflicting data on the relationship between viral evolution and disease progression and may provide a useful framework for evaluating immune damage and recovery in untreated and treated HIV infection."

"We think we can now predict the progression of the disease three of four years before the onset of clinical symptoms of AIDS," said Mullins. "This capability is important, because by the time it is recognized that someone has entered the clinical phase, it may be too late to treat effectively. Furthermore, current treatments greatly suppress but do not eliminate HIV from the body. Hence, treatments need to be taken throughout the lifespan of the infected person. However, these drugs may produce serious side effects, and financial costs of these therapies are too great for many individuals to even consider, especially in developing countries. The ability to predict the onset of disease may therefore eventually help target therapies to the time that they might be most effective at blocking the onset of clinical AIDS.

"However, the considerable challenge now is to create a viable lab test based on this research, so that it can be useful in clinical application."
-end-
For more information contact Dr. Raj Shankarappa at (206) 616-4282 or <rajs@u.washington.edu >; and Dr. James Mullins at (206) 616-1851 or <jmullins@u.washington.edu >.

University of Washington

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.